The addition of pethidine to epidural bupivacaine in labour--effect of changing bupivacaine strength.
The effects of varying the strength of bupivacaine used in epidurals for the relief of labour pain was examined. The trial randomly allocated sixty women in the first stage of labour to one of three groups. All women were of ASA status 1 or 2 and had uncomplicated pregnancies. Subjects in each group received pethidine 25 mg in 10 ml of either 0.125%, 0.1875%, or 0.25% bupivacaine. Pain scores for each patient were then assessed over the following thirty minutes. Duration of analgesia and subsequent dose requirements were examined. No difference in pain scores between groups at thirty minutes after injection of the test solutions was found. The 0.25% solution group did however have a more rapid onset of analgesia with the majority of patients in this group achieving their maximum effect between ten and twenty minutes after injection. Duration of analgesia was not prolonged by using the stronger solutions. This study suggests that when epidural pethidine 25 mg is added to local anaesthetic solutions of bupivacaine, adequate analgesia for the first stage of labour is achieved with the 0.125% bupivacaine solution. The use of stronger solutions of bupivacaine achieves no greater degree of analgesia nor longer duration of action, although the onset of analgesia may be faster with the stronger solutions. Further investigations are needed to determine if 25 mg of pethidine is the best choice of dose to use under these circumstances.
Handley
G
G
Department of Anaesthetics and Intensive Care, Gold Coast Hospital, Southport, Queensland, Australia.
Perkins
G
G
D000328:Adult; D015360:Analgesia, Epidural; D016362:Analgesia, Obstetrical; D000767:Anesthesia, Epidural; D000773:Anesthesia, Obstetrical; D001034:Apgar Score; D002045:Bupivacaine / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D036861:Delivery, Obstetric; D004311:Double-Blind Method; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007747:Labor Stage, First; D008614:Meperidine / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D010147:Pain Measurement; D011247:Pregnancy; D013997:Time Factors
D008614:Meperidine; D002045:Bupivacaine